Osteoarthritis

Zoetis Gains EU Approval for 3-Month Feline Osteoarthritis Treatment

Zoetis’ newly approved Portela® (relfovetmab) becomes the first feline osteoarthritis treatment offering three months of pain relief from a single injection, with EU launch expected in 2026.

Zoetis’ Lenivia® Nears Global Rollout as New Long-Acting Osteoarthritis Therapy for Dogs

Zoetis’ Lenivia® (izenivetmab) receives Health Canada approval and a positive opinion from the European Medicines Agency, paving the way for the world’s first three-month monoclonal antibody therapy for canine osteoarthritis pain.

Topics

Zoetis Gains EU Approval for 3-Month Feline Osteoarthritis Treatment

Zoetis’ Lenivia® Nears Global Rollout as New Long-Acting Osteoarthritis Therapy for Dogs

Zoetis to Acquire Neogen’s Animal Genomics Business for $160 Million, Expanding Precision Animal Health Portfolio

Zoetis to Participate in Bank of America 2026 Animal Health Summit

Tartar Shield Launches ‘Second Smile’ Initiative Integrating Preventive Dental Care Into Shelter Adoptions

Most U.S. Pet Owners Report High Satisfaction with Their Veterinary Practice, AVMA Data Show

FDA Grants Emergency Use Authorization for NexGard Products to Treat New World Screwworm in Dogs and Cats

FDA Approves NUMELVI™, First Second-Generation JAK Inhibitor for Canine Allergic Dermatitis